(Alliance News) - Genedrive PLC on Monday said it received World Health Organisation prequalification for its Genedrive HCV ID kit.
Genedrive' shares ended 46% higher at 198.00 pence.
The company had found it difficult to complete an independent clinical test of the HCV ID kit, which tests for hepatitis C and had therefore previously not been able to qualify the kit with the WHO.
This prequalification means it will be included in the WHO's list of prequalified in vitro diagnostics and will be "eligible to participate in the procurement processes of [United Nations] agencies". WHO member states are encouraged to use this list in making producrement decision.
Chief Executive David Budd said: "We are delighted to have reached this important milestone in the evolution of our company and in our efforts to tackle the real problem of undiagnosed HCV infection in low and middle income countries. The WHO PQ process itself was very rigorous and we are pleased to have our HCV products validated through their independent audit and laboratory testing processes. WHO PQ will support the commercial processes of our distribution partners in many countries and evidences genedrive's product development and vigilance processes to this important agency."
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Genedrive (GDR)